Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.

Hair loss treatments, specifically experiences with Redensyl as well as other treatments such as Minoxidil, finasteride and RU58841.

Minoxidil, finasteride, and RU58841 are discussed as hair loss treatments. Users express skepticism about certain products, with some preferring simpler options like caffeine-based products.

The conversation discusses the use of RU58841 for hair loss, focusing on its side effects, standardization issues, and user experiences. The user also inquires about the use of other treatments like minoxidil, finasteride, and microneedling.

A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

The conversation discusses hair cloning progress and mentions treatments like Minoxidil, finasteride, and RU58841. Users also talk about hair transplants and their effectiveness.

People are not using RU58841 for hair loss because it's not FDA approved, lacks long-term safety data, and is difficult to obtain and verify. They prefer FDA-approved treatments like minoxidil, finasteride, ketoconazole shampoo, and microneedling.

A user is exploring personalized topical formulations for hair loss from Roots By Genetics Art, specifically interested in the GA-5 Power Restore formulation containing dutasteride, minoxidil, and other ingredients. They seek opinions on the effectiveness and value of these products.

RU58841 is not FDA approved, and users are discussing its availability and legitimacy in India, with some mentioning brands like Vantanex and Capomil. One user warns about the risk of gyno from RU58841, advising to stop use at the first sign of sensitivity.

The conversation discusses skepticism about DHT blocker supplements for hair loss, with many users recommending proven treatments like finasteride and minoxidil instead. Some users shared personal experiences with alternative treatments like beta-sitosterol and saw palmetto, noting side effects and limited effectiveness.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

The conversation is about hair loss treatments, specifically Minoxidil (Min) and Finasteride (Fin). The original poster is considering using Min and other treatments but is hesitant about Fin, while the responses vary, with some advocating for early use of Fin and others warning about potential side effects.

Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.

A user is exploring Kadeso, a product with Capilia Longa™ for hair regrowth, and seeks real-world experiences, comparing it to Minoxidil and Finasteride. They are interested in results, timeframe, side effects, and the credibility of the product's founder.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

A questionable paper which suggests that 5% topical spironolactone is more effective than 0.1% topical finasteride for treating hair loss. It should be taken with a grain of salt due to the journal it was published in.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

Pyrilutamide is discussed as an effective hair loss treatment by some users, despite skepticism due to limited data and underwhelming trial results. Users compare it to finasteride, minoxidil, and RU58841, with some expressing interest in its potential as an adjunct treatment.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

The conversation discusses the legitimacy of Minoxidil Express for hair loss treatment. It mentions using Minoxidil, Finasteride, and RU58841.

Hair loss treatments, including microneedling, minoxidil, finasteride and RU58841; the efficacy of these treatments; criticisms of Kevin Mann's content related to his selective data presentation and biases towards certain treatments; and other topics such as DHT being labeled a "trash hormone" and critiques of other hairloss YouTubers.

The conversation is about the delay in Breezula's phase 3 trials and skepticism regarding its effectiveness compared to other treatments like RU58841 and Pyrilutamide. Some users prefer safety over effectiveness, while others express frustration with the slow progress and doubt Breezula will be a significant treatment for hair loss.

The user switched from prescribed topical minoxidil and finasteride to stronger grey market alternatives, hoping for better hair growth but experiencing shedding. Concerns were raised about the legitimacy and safety of grey market products, with suggestions to use prescribed medications instead.

The conversation is about choosing between gray market Pyrilutamide and the official Kintor version for hair loss treatment. Users share mixed experiences, with some finding both versions effective and others not seeing results.

The conversation is about individuals considering waiting for Breezula to treat hair loss instead of using Finasteride due to concerns about side effects. Some are opting for Finasteride now, while others are wary of its impact on neurosteroids.

The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.

The conversation is about hair loss treatments, specifically a stack including topical Ashwagandha, Copper Peptide, Gotu Kola, Ketoconazole, and PDA. One user found Topical and Sub-Q GHK-CU effective.